Memory Pharmaceuticals Reviewed by NeuroInvestment

CARDIFF, CA--(MARKET WIRE)--Jun 5, 2007 -- NI Research has released the June issue of NeuroInvestment, which reviews the status and prospects of treatments for memory disorders such as MCI (Mild Cognitive Impairment) and AAMI (Age-Associated Memory Impairment). While much attention is paid to the burgeoning prevalence of Alzheimer’s, there is an enormous, albeit much more hidden, epidemic of less severe forms of memory disturbance, a large proportion (though not all) of which is a precursor to dementia. Besides the subjective distress experienced by people who find everyday information increasingly slipping through their fingers, slowing the progression of MCI/AAMI might also delay the onset of dementia -- impacting the major societal healthcare issue for decades to come.

MORE ON THIS TOPIC